Goldman Sachs initiated coverage of Viatris (VTRS) with a Neutral rating and $10 price target The firm awaits clarity on the company’s growth outlook given current structural dynamics in the core business and believes consensus estimates appear fair. On the generics side, it expects modest growth as Goldman monitors Viatris’ ability to more meaningfully off-set legacy product erosion via new product launches and portfolio optimization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS: